Patents Assigned to Amgen
  • Patent number: 5874399
    Abstract: A progenitor B cell stimulating factor which promotes the formation of pre-B cells is described. DNA sequences encoding same and methods of production and purification of the factor are also disclosed. The factor is used in the treatment of hematopoietic disorders and in bone marrow transplantation.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: February 23, 1999
    Assignee: Amgen Inc.
    Inventor: Babru Bahan Samal
  • Patent number: 5874075
    Abstract: The invention relates to stable compositions of proteins and related methods wherein a protein capable of transitioning into the molten globular state is contacted with a negatively charged lipid vesicle, thereby stabilizing the protein against thermally-induced aggregation, denaturation, and loss of activity. The protein:phospholipid complex directly stabilizes the secondary and tertiary structure of the protein, and the compositions are useful in high temperature formulations and in novel delivery vehicles.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: February 23, 1999
    Assignee: Amgen Inc.
    Inventors: David Collins, Younsik Cha, David Brems
  • Patent number: 5871956
    Abstract: A synthetic DNA sequence and its genetic equivalents are disclosed which sequences are capable, when used in a recombinant DNA method, of directing production of a serine protease inibitor protein. Recombinant DNA methods for the production of serine protease inhibitor proteins are also disclosed. These methods incorporate either the synthetic DNA sequence of the present invention or natural DNA sequences isolated from human cDNA or genomic libraries.
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: February 16, 1999
    Assignee: Amgen Inc.
    Inventors: Pradip K. Bandyopadhyay, Stephen P. Eisenberg, Gary L. Stetler, Robert C. Thompson
  • Patent number: 5869055
    Abstract: The invention relates to anti-inflammatory polypeptides comprising soluble CD14 related polypeptides having amino acids at position 7-10 that are different from the native sequence or having amino acids 1-14 deleted.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 9, 1999
    Assignee: Amgen, Inc.
    Inventors: Shao-Chieh Juan, Henri S. Lichenstein, Samuel D. Wright
  • Patent number: 5864031
    Abstract: The present invention provides nuclease resistant 5'-dithio-modified oligonucleotides that are useful in nucleic acid therapeutics and diagnostics. The novel modified oligonucleotides have at least one 5'-dithioate linkage, wherein both the oxygen atom at the 5'-position (5'-bridging oxygen) and at least one of the non-bridging oxygen atoms of a naturally occurring phosphodiester linkage are independently replaced with a single sulfur atom. The invention also provides a polymer-supported method for making 5'-dithio-modified and 5'-thio-modified oligonucleotides as well as novel monomeric nucleoside and nucleotide intermediates useful in the synthetic method.
    Type: Grant
    Filed: July 29, 1994
    Date of Patent: January 26, 1999
    Assignee: Amgen Inc.
    Inventors: Sandra E. Russo-Rodriguez, Tepper M. Koga
  • Patent number: 5863892
    Abstract: A method of accelerating corneal wound healing in the corneal anterior stroma and/or improving the quality of wound healing in a mammal comprises: (1) providing an ophthalmically compatible solution of platelet-derived growth factor; and (2) applying the solution to the cornea of a mammal at the time of or subsequent to occurrence of a corneal wound in a quantity sufficient to accelerate clinically detectable healing, the healing being accelerated through proliferation of epithelial cells and/or keratocytes of the cornea stimulated by application of the platelet-derived growth factor to the cornea. The platelet-derived growth factor can be selected from the group consisting of the AA isoform, the AB isoform, the BB isoform, and mixtures thereof. A preferable form of platelet-derived growth factor is a recombinantly-derived refolded B-chain homodimer of 119 amino acids, having the amino acid sequence of SEQ ID NO: 1. The concentration of platelet-derived growth factor in the solution can be from about 10 .mu.
    Type: Grant
    Filed: June 9, 1994
    Date of Patent: January 26, 1999
    Assignees: Allergan Inc., Amgen Inc.
    Inventors: Michael E. Stern, Larry A. Wheeler, Margery A. Nicolson
  • Patent number: 5863732
    Abstract: The present invention makes possible the catalytic production of sequence specific oligonucleotides through the use of a specially designed template sequence. The reaction can be made to proceed isothermally in the presence of an excess of nucleoside triphosphates, an agent for polymerization, and a cutting agent. Because the process is catalytic with respect to the template sequence, an unlimited amount of oligonucleotide product can theoretically be generated from a single molecule of template. Where the process is initiated by the presence of a nucleic acid target sequence, the method of the present invention can be used for diagnostic purposes as an amplification method to improve sensitivity. Diagnostic sensitivity can be further enhanced by employing a cascade of these template sequences.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: January 26, 1999
    Assignee: Amgen Inc.
    Inventor: Rodney M. Richards
  • Patent number: 5861315
    Abstract: Stem cell factor in combination with soluble interleukin-6 receptor, interleukin-6, for gp130 signaling, supports the proliferation, differentiation and terminal maturation of blood cells from normal human hematopoietic multipotential cells.
    Type: Grant
    Filed: October 16, 1996
    Date of Patent: January 19, 1999
    Assignees: Amgen Inc., Tosoh Corporation
    Inventor: Tatsutoshi Nakahata
  • Patent number: 5859197
    Abstract: Disclosed are DNA and amino acid sequences for a novel polypeptide termed Neuritin which is expressed primarily in selected regions of the brain.
    Type: Grant
    Filed: October 9, 1997
    Date of Patent: January 12, 1999
    Assignees: Amgen Inc., Yeda Research & Development Co, Ltd.
    Inventors: Lars E. Theill, Gregory S. Naeve, Yoav Citri, deceased
  • Patent number: 5858977
    Abstract: A method and pharmaceutical compositions are described for the use of keratinocyte growth factor to treat diabetes mellitus in mammals.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: January 12, 1999
    Assignee: Amgen Inc.
    Inventors: Sharon Lea Aukerman, Glenn Francis Pierce
  • Patent number: 5856298
    Abstract: Erythropoietin isoforms having a specific number of sialic acids per erythropoietin molecule are disclosed. Also disclosed are mixtures of such isoforms, pharmaceutical compositions containing such isoforms or mixtures thereof and methods of obtaining the erythropoietin isoforms.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: January 5, 1999
    Assignee: Amgen Inc.
    Inventor: Thomas Wayne Strickland
  • Patent number: 5849705
    Abstract: Schwann cells can be treated in vivo to survive longer and to proliferate by contacting them with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: December 15, 1998
    Assignee: Amgen Inc.
    Inventors: Josette Francoise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer
  • Patent number: 5849883
    Abstract: Processes for isolating and purifying granulocyte colony stimulating factor (G-CSF) from a G-CSF producing microorganism are disclosed. The simplified processes include steps of lysing the microorganism and separating insoluble material containing G-CSF from soluble proteinaceous material; extracting the material with deoxycholate (optionally); solubilizing and oxidizing the G-CSF in the presence of a denaturant solubilizing agent and an oxidizing agent; removing the denaturant solubilizing agent from the G-CSF; subjecting the G-CSF to ion exchange chromatography; and recovering the purified G-CSF; yet excludes other cumbersome purification steps.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: December 15, 1998
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Allan L. Miller, Jeffrey W. Andresen
  • Patent number: 5843791
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignee: Amgen Boulder Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Patent number: 5843678
    Abstract: A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.
    Type: Grant
    Filed: April 16, 1997
    Date of Patent: December 1, 1998
    Assignee: Amgen Inc.
    Inventor: William J. Boyle
  • Patent number: 5837681
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates more specifically to methods for treating sensorineural hearing loss.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: November 17, 1998
    Assignee: Amgen Inc.
    Inventor: Ella Magal
  • Patent number: 5830857
    Abstract: A method is described for the therapeutic use of brain-derived neurotrophic factor (BDNF) to treat epilepsy.
    Type: Grant
    Filed: July 14, 1995
    Date of Patent: November 3, 1998
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Antoine Depaulis, Paul Feltz, Yves Larmet, Christian Marescaux, Hiroyuki Nawa
  • Patent number: 5831062
    Abstract: The present invention relates generally to a human interferon consensus gene useful for expression in eucaryotic systems and gene therapy. In particular, the present invention relates to treatment of cancer and cell proliferation disorders through use of viral vectors to deliver and express the human interferon consensus gene in the cells and/or tumors of a patient.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: November 3, 1998
    Assignee: Amgen Inc.
    Inventors: Milton W. Taylor, Lawrence M. Blatt
  • Patent number: 5830705
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: July 15, 1996
    Date of Patent: November 3, 1998
    Assignee: Amgen Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 5824784
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: October 20, 1998
    Assignee: Amgen Inc.
    Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince